Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 35 | ECE2014 | Next issue

16th European Congress of Endocrinology

Oral Communications

Endocrine Tumours

ea0035oc10.1 | Endocrine Tumours | ECE2014

Blood-borne and tissue microRNAs in adrenocortical tumours: affected pathways and diagnostic relevance

Igaz Peter , Szabo Diana Rita , Zsippai Adrienn , Szabo Peter M , Nagy Zoltan , Toth Miklos , Luconi Michaela , Mannelli Massimo , Patocs Attila , Racz Karoly

Background: The differential expression of tissue microRNAs in benign and malignant adrenocortical tumours has been described in several studies including ours. Novel data show that microRNAs are also present in the bloodstream and can be exploited as minimally invasive markers of malignancy.Objective: To analyze the microRNAs expressed in different studies by an in silico approach and to establish the molecular pathways affected. Furthermore, circulatin...

ea0035oc10.2 | Endocrine Tumours | ECE2014

The cytotoxic effect of sunitinib on human bronchial carcinoid cell lines and primary cultures is counteracted by EGF and IGF-1 but not by VEGF

Gagliano Teresa , Gennari Giulia , Tassinari Martina , Bellio Mariaenrica , Gentilin Erica , Benfini Katiuscia , Uberti Ettoredegli , Zatelli Maria Chiara

Background: Bronchial carcinoids (BC) are rare tumors originating from endocrine cells dispersed in the respiratory epithelium. The main BC treatment is surgery, which is not feasible for large, infiltrating and metastatic disease. In these settings, medical therapy is often tried. Therefore it is important to identify new therapeutic targets and new molecules capable of providing adequate medical treatment for patients with BC. Sunitinib, is an oral, small-molecule, multi-tar...

ea0035oc10.3 | Endocrine Tumours | ECE2014

The NMU signaling controls cancer progression of human RL95-2 endometrial cancer cells through cell motility maintenance

Lin Ting-Yu , Luo Ching-Wei

In addition to regular functions in controlling muscle contraction and energy homeostasis, recent studies have reported the neuromedin U (NMU) signaling plays important roles in cancer progression. Intriguingly, we observed that both NMU and one of its receptors, NMUR2, are highly expressed and co-localized in the mouse uterine endometrial luminal epithelium during the estrus stage. We also found that the NMU transcript is dramatically augmented in patients with high-...

ea0035oc10.4 | Endocrine Tumours | ECE2014

Mast cell interactions at tumour interface drive progression in human prostate cancer

Risbridger Gail , Ellem Stuart , Taylor Renea , Frydenberg Mark , Pook David , Pedersen John , Bioresource APC , Hashimoto Kohei , Seach Natalie , Clark Ashlee , Hutmacher Dietmar , Pardo Elena

Introduction: Prostate cancer is hormone dependent and regulated by a balance of androgens as well as estrogens. Regulatory control is also exerted by the tumor microenvironment including cancer-associated fibroblasts (CAFs), and immune cells. Although patient derived xenografts (PDX) commonly used to study the functional effects of CAFs, the method is not quantitative, is lengthy, technically challenging and the xenografts are placed in immune suppressed hosts excluding immun...

ea0035oc10.5 | Endocrine Tumours | ECE2014

Molecular mechanisms underlying the unexpected promoting effects of mifepristone on murine testicular Leydig cell tumorigenesis

Chrusciel Marcin , Ponikwicka-Tyszko Donata , Stelmaszewska Joanna , Li Xiangdong , Huhtaniemi Ilpo , Toppari Jorma , Wolczynski Slawomir , Rahman Nafis

Progesterone (P4) treatment has been shown to have a clear modulating effect on murine Leydig tumor cell (mLTC-1) function, including downregulation of luteinizing hormone receptor. We hypothesized that P4 would stimulate, whereas an antiprogestine mifepristone (MF) block tumor progression in vivo in a transgenic (TG) murine Leydig cell tumor model (inhibin-α promoter-driven SV40 T-antigen (inhα/Tag)) and act similarly on cell proliferation in vitro...